MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 532784 | Name: SR9011
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR9011 is a REV-ERB-α/β agonist that increases the constitutive repression of genes regulated by REV-ERBα and REV-ERBβ with IC50 values of 790 and 560 nM, respectively.

Chemical Structure

SR9011
CAS#1379686-29-9

Theoretical Analysis

MedKoo Cat#: 532784

Name: SR9011

CAS#: 1379686-29-9

Chemical Formula: C23H31ClN4O3S

Exact Mass: 478.1805

Molecular Weight: 479.04

Elemental Analysis: C, 57.67; H, 6.52; Cl, 7.40; N, 11.70; O, 10.02; S, 6.69

Price and Availability

Size Price Availability Quantity
5mg USD 400.00 2 weeks
25mg USD 1,150.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR9011; SR 9011; SR-9011.
IUPAC/Chemical Name
3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide
InChi Key
PPUYOYQTTWJTIU-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29)
SMILES Code
O=C(N1CC(CN(CC2=CC=C(Cl)C=C2)CC3=CC=C([N+]([O-])=O)S3)CC1)NCCCCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, DMF, and ethanol
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SR9011 is a REV-ERB agonist that increases the constitutive repression of genes regulated by REV-ERBα and REV-ERBβ with IC50 values of 790 and 560 nM, respectively. It has no activity at other nuclear receptors.
In vitro activity:
SR9011 suppressed proliferation of the breast cancer cell lines regardless of their ER or HER2 status but had no effect on MCF10A cell proliferation. SR9011 appears to pause the cell cycle of the breast cancer cells prior to M phase. Cyclin A was identified as a direct target gene of REV-ERB, suggesting that suppression of expression of this cyclin by SR9011 may mediate the cell cycle arrest. Reference: Biochem Pharmacol. 2015 Aug 15;96(4):315-22. https://pubmed.ncbi.nlm.nih.gov/26074263/
In vivo activity:
In isolated primary microglia from rat pups, SR9011 disrupted clock gene expression, altered cytokine balance, and reduced phagocytic activity and mitochondrial function in microglia. Reference: Front Immunol. 2020 Sep 25;11:550145. https://pubmed.ncbi.nlm.nih.gov/33101272/
Solvent mg/mL mM comments
Solubility
DMF 30.0 62.63
DMSO 30.0 62.63
Ethanol 14.0 29.23
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 479.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Geldof L, Deventer K, Roels K, Tudela E, Van Eeno P. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Int J Mol Sci. 2016 Oct 3;17(10):1676. doi: 10.3390/ijms17101676. PMID: 27706103; PMCID: PMC5085709. 2. Wang Y, Kojetin D, Burris TP. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. Biochem Pharmacol. 2015 Aug 15;96(4):315-22. doi: 10.1016/j.bcp.2015.06.010. Epub 2015 Jun 12. PMID: 26074263; PMCID: PMC4526361. 3. Wolff SEC, Wang XL, Jiao H, Sun J, Kalsbeek A, Yi CX, Gao Y. The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia. Front Immunol. 2020 Sep 25;11:550145. doi: 10.3389/fimmu.2020.550145. PMID: 33101272; PMCID: PMC7546349.
In vitro protocol:
1. Geldof L, Deventer K, Roels K, Tudela E, Van Eeno P. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Int J Mol Sci. 2016 Oct 3;17(10):1676. doi: 10.3390/ijms17101676. PMID: 27706103; PMCID: PMC5085709. 2. Wang Y, Kojetin D, Burris TP. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. Biochem Pharmacol. 2015 Aug 15;96(4):315-22. doi: 10.1016/j.bcp.2015.06.010. Epub 2015 Jun 12. PMID: 26074263; PMCID: PMC4526361.
In vivo protocol:
1. Wolff SEC, Wang XL, Jiao H, Sun J, Kalsbeek A, Yi CX, Gao Y. The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia. Front Immunol. 2020 Sep 25;11:550145. doi: 10.3389/fimmu.2020.550145. PMID: 33101272; PMCID: PMC7546349.
1: Gupta S, Ahuja N, Kumar S, Arora R, Kumawat S, Kaushal V, Gupta P. Rev-erbα regulate neurogenesis through suppression of Sox2 in neuronal cells to regenerate dopaminergic neurons and abates MPP+ induced neuroinflammation. Free Radic Biol Med. 2024 Oct;223:144-159. doi: 10.1016/j.freeradbiomed.2024.07.025. Epub 2024 Jul 29. PMID: 39084577. 2: Kumar S, Arora R, Gupta S, Ahuja N, Bhagyaraj E, Nanduri R, Kalra R, Khare AK, Kumawat S, Kaushal V, Sharma M, Gupta P. Nuclear receptor Rev-erbα role in fine-tuning erythropoietin gene expression. Blood Adv. 2024 Jul 23;8(14):3705-3717. doi: 10.1182/bloodadvances.2023012228. PMID: 38748870; PMCID: PMC11296239. 3: Nakazato R, Matsuda Y, Ijaz F, Ikegami K. Circadian oscillation in primary cilium length by clock genes regulates fibroblast cell migration. EMBO Rep. 2023 Dec 6;24(12):e56870. doi: 10.15252/embr.202356870. Epub 2023 Nov 16. PMID: 37971148; PMCID: PMC10702818. 4: Prasad C, Hahn K, Duraisamy SK, Salathe MA, Huang SK, Burris TP, Sundar IK. Rev-erbα agonists suppresses TGFβ1-induced fibroblast-to-myofibroblast transition and pro-fibrotic phenotype in human lung fibroblasts. Biochem Biophys Res Commun. 2023 Aug 20;669:120-127. doi: 10.1016/j.bbrc.2023.05.092. Epub 2023 May 24. PMID: 37269594; PMCID: PMC11034855. 5: Yuan B, Shi K, Zha J, Cai Y, Gu Y, Huang K, Yue W, Zhai Q, Ding N, Ren W, He W, Xu Y, Wang T. Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway. Cell Death Dis. 2023 Jan 21;14(1):51. doi: 10.1038/s41419-022-05545-7. PMID: 36681687; PMCID: PMC9867777. 6: Tiwari D, Ahuja N, Kumar S, Kalra R, Nanduri R, Gupta S, Khare AK, Bhagyaraj E, Arora R, Gupta P. Nuclear receptor Nr1d1 alleviates asthma by abating GATA3 gene expression and Th2 cell differentiation. Cell Mol Life Sci. 2022 May 21;79(6):308. doi: 10.1007/s00018-022-04323-0. PMID: 35596832; PMCID: PMC11073070. 7: Kwak YB, Yu J, Yoo HH. A quantitative method for the simultaneous detection of SR9009 and SR9011 in equine plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. Drug Test Anal. 2022 Aug;14(8):1532-1538. doi: 10.1002/dta.3271. Epub 2022 Apr 19. PMID: 35396832. 8: Wolff SEC, Wang XL, Jiao H, Sun J, Kalsbeek A, Yi CX, Gao Y. The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia. Front Immunol. 2020 Sep 25;11:550145. doi: 10.3389/fimmu.2020.550145. PMID: 33101272; PMCID: PMC7546349. 9: Guo DK, Zhu Y, Sun HY, Xu XY, Zhang S, Hao ZB, Wang GH, Mu CC, Ren HG. Pharmacological activation of REV-ERBα represses LPS-induced microglial activation through the NF-κB pathway. Acta Pharmacol Sin. 2019 Jan;40(1):26-34. doi: 10.1038/s41401-018-0064-0. Epub 2018 Jun 27. PMID: 29950615; PMCID: PMC6318300. 10: Amador A, Kamenecka TM, Solt LA, Burris TP. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009. Biochem Pharmacol. 2018 Apr;150:1-8. doi: 10.1016/j.bcp.2018.01.009. Epub 2018 Jan 23. PMID: 29355503. 11: Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, Plikus MV, Verma IM, Panda S. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355. doi: 10.1038/nature25170. Epub 2018 Jan 10. PMID: 29320480; PMCID: PMC5924733. 12: Nakazato R, Hotta S, Yamada D, Kou M, Nakamura S, Takahata Y, Tei H, Numano R, Hida A, Shimba S, Mieda M, Hinoi E, Yoneda Y, Takarada T. The intrinsic microglial clock system regulates interleukin-6 expression. Glia. 2017 Jan;65(1):198-208. doi: 10.1002/glia.23087. Epub 2016 Oct 11. PMID: 27726182. 13: Geldof L, Deventer K, Roels K, Tudela E, Van Eeno P. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Int J Mol Sci. 2016 Oct 3;17(10):1676. doi: 10.3390/ijms17101676. PMID: 27706103; PMCID: PMC5085709. 14: Thevis M, Schänzer W. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):635-51. doi: 10.1002/rcm.7470. PMID: 26842585. 15: Ercolani L, Ferrari A, De Mei C, Parodi C, Wade M, Grimaldi B. Circadian clock: Time for novel anticancer strategies? Pharmacol Res. 2015 Oct;100:288-95. doi: 10.1016/j.phrs.2015.08.008. Epub 2015 Aug 28. PMID: 26319800. 16: Wang Y, Kojetin D, Burris TP. Anti-proliferative actions of a synthetic REV- ERBα/β agonist in breast cancer cells. Biochem Pharmacol. 2015 Aug 15;96(4):315-22. doi: 10.1016/j.bcp.2015.06.010. Epub 2015 Jun 12. PMID: 26074263; PMCID: PMC4526361. 17: Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nat Commun. 2014 Dec 23;5:5759. doi: 10.1038/ncomms6759. PMID: 25536025; PMCID: PMC4495958. 18: Shea SA. Obesity and pharmacologic control of the body clock. N Engl J Med. 2012 Jul 12;367(2):175-8. doi: 10.1056/NEJMcibr1204644. PMID: 22784121. 19: Bass J. Drug discovery: Time in a bottle. Nature. 2012 May 2;485(7396):45-6. doi: 10.1038/485045a. PMID: 22552089. 20: Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-8. doi: 10.1038/nature11030. PMID: 22460951; PMCID: PMC3343186.